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Jesu´s Avila
Editor of FEBS Letters since 1997Jesu´s Avila is a scientist whose interests have led him into
many branches of science. He ﬁrst studied organic and physical
chemistry at the University of Madrid, while maintaining a
side interest in molecular biology. He then chose to do his
PhD in this subject, graduating in 1971. When he moved to
the NIH (Bethesda, USA), he changed ﬁelds once again, this
time, researching an oncogenic virus, SV40. In 1975, he re-
turned to Spain for a position at the CSIC in Madrid, taking
the opportunity to focus on the cytoskeleton, which ﬁnally
led him into his current work involving neuroscience. ‘‘Study-
ing neurons is a privilege for me because I ﬁnd them beautiful;
neurons have a lot of complicated extensions and complex
symmetries that other cells don’t possess,’’ he says. Since
1987, Jesu´s has been a professor at the Center of Molecular
Biology, at the University Auto´noma of Madrid. Dr. Avila
handles papers for FEBS Letters that deal with neuron mor-
phology, the cytoskeleton and the molecular mechanisms in-
volved in neuropathies.
What does your lab do?
We study the development, degeneration and regeneration of
neurons. We focus on the how the cytoskeleton is involved in
the changes in neural morphology during development, for in-
stance, how axons are extended and how dendrites organize
themselves to form synapses. We have found that microtubules
are important for this development, along with other proteins,
such as tau. Once we found the role tau played, our research also
branched into studying neural degeneration. We focus mainly
on Alzheimer’s disease, but also study other neurodegenerative
disorders such as tauopathies and ataxias. The third part of our
research deals with the regeneration of neurons, attempting to
repair the eﬀects of neurodegeneration. We use animal models
for this, which mimic the progression of the disease.
What happens when Alzheimer’s develops?
There are two aberrant structures formed in a brain when Alz-
heimer’s develops. The ﬁrst are senile plaques, which are
formed by aggregated amyloid peptides. The second are neuro-
ﬁbrillary tangles, which contain ﬁlaments of hyperphosphoryl-
ated tau. These structures cause neurons to retract their axon
processes. The neurons eventually die. The severity of senile
dementia is directly related to the quantity of these aberrant
structures. It is estimated that 25–28 million people in the world
have Alzheimer’s, so that is why it is important to ﬁnd a cure!Interview by Tine WalmaHow is the protein tau involved in Alzheimer’s?
Each neuron needs to maintain an internal cytoskeleton to fa-
vour the formation of synapses with other neurons. Tau binds
to, and stabilizes microtubules, allowing neural extensions to0014-5793/$32.00  2006 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2006.09.024grow and make these connections. In Alzheimer’s disease,
tau is post-translationally phosphorylated, which cause it
self-aggregate into tangles. In other neuropathies, tau is actu-
ally mutated, causing the tangles to then form.
How do you go about trying to cure neuropathies?
The ﬁrst step is to develop animal models that mimic the dis-
ease progression, accurately and kinetically. And then, we will
try to revert the progress of the disease at diﬀerent stages. Neu-
rodegeneration originates in the entorhinal cortex, before mov-
ing to the hippocampus and from there to the cortex. We
would like to ﬁrst develop a good model and then to try to stop
the progression of the degeneration as soon as possible.
What papers are you most proud of?
My ﬁrst publication was actually a letter to the editor in
Nature, on RNA polymerase and transcription [1]. I was very
proud of that. But I am fond of other papers too, such as
one in FEBS Letters, which deals with the role of tau in the
formation of tangles [2]. But my favourite paper is from 1984,
in which we were the ﬁrst to indicate how proteins such as
tau bind to, and stabilize, microtubules [3]. Amore recent paper
of note describes, for the ﬁrst time, the use of transplanted
olfactory bulb glial cells to recover paraplegic rats [4]. It de-
scribes rats that were unable to walk, recovering this ability.
And lastly, I like a paper we wrote on developing amousemodel
for Alzheimer’s disease, one that is kinetically relevant [5].
Where did the idea of using olfactory cells come from?
That was the idea of two people, Doucette from Canada and
Nieto-Sampedro from Spain [6,7]. Because cells are constantly
regenerating in the olfactory organ, they thought that the cen-
tral nervous system could beneﬁt from this ability.
What do you like most about your work?
Well, I particularly like to learn and know things. I ﬁnd it beau-
tiful that every day something new happens, that we can learn
from other people, read about their lives and work, and beneﬁt
from it. But in senile diseases, the three aspects of our human-
ity, the memory, understanding and will power disappear, and
this can be related to the behaviour of proteins, such as tau.
This perhaps explains my interest in curing neurodegenerative
diseases. I would like to determine how a single protein can
cause the loss of these functions. Humanity, essentially.Contact Information
Centro de Biologia Molecular ‘‘Severo Ochoa’’ (CSIC-UAM),
Universidad Autonoma de Madrid, Madrid, Spain
E-mail address: javila@cbm.uam.es
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